Department of Radiological Sciences, University of California Irvine, Orange, CA, USA.
Department of Hematology and Oncology, Emory University Winship Cancer Institute, Atlanta, GA, USA.
J Oncol Pharm Pract. 2023 Dec;29(8):1957-1964. doi: 10.1177/10781552231161823. Epub 2023 Mar 7.
To pilot test a mobile health intervention using a CONnected CUstomized Treatment Platform that integrates a connected electronic adherence monitoring smartbox and an early warning system of non-adherence with bidirectional automated texting feature and provider alerts.
In total, 29 adult women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer and a prescription for palbociclib were asked to complete a survey and participate in a CONnected CUstomized Treatment Platform intervention, including use of a smartbox for real-time adherence monitoring, which triggered text message reminders for any missed or extra dose, and referrals to (a) participant's oncology provider after three missed doses or an episode of over-adherence, or (b) a financial navigation program for any cost-related missed dose. Use of smartbox, number of referrals, palbociclib adherence, CONnected CUstomized Treatment Platform usability measured by System Usability Scale, and changes in symptom burden and quality of life were assessed.
Mean age was 57.6 and 69% were white. The smartbox was used by 72.4% of participants, with palbociclib adherence rate of 95.8%±7.6%. One participant was referred to oncology provider due to missed doses and one was referred to financial navigation. At baseline, 33.3% reported at least one adherence barrier including inconvenience to get prescription filled, forgetfulness, cost, and side effects. There were no changes in self-reported adherence, symptom burden or quality of life over 3 months. CONnected CUstomized Treatment Platform usability score was 61.9 ± 14.2.
The CONnected CUstomized Treatment Platform interventions is feasible, resulting in a high palbociclib adherence rate without any decline in overtime. Future efforts should focus on improving usability.
试用一种移动健康干预措施，该措施使用连接的定制化治疗平台，该平台集成了连接的电子依从性监测智能盒和非依从性的预警系统，具有双向自动短信功能和提供者警报。
共有 29 名激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌成年女性和帕博西利布处方，要求他们完成一项调查并参与连接的定制化治疗平台干预，包括使用智能盒进行实时依从性监测，对于任何漏服或多服的药物，智能盒会触发短信提醒，并向（a）患者的肿瘤医生转介，在漏服三剂或出现过度依从的情况下，或（b）在发生任何与费用相关的漏服时向财务导航计划转介。评估智能盒的使用情况、转介次数、帕博西利布的依从性、系统可用性量表测量的连接的定制化治疗平台的可用性，以及症状负担和生活质量的变化。
平均年龄为 57.6 岁，69%为白人。72.4%的参与者使用了智能盒，帕博西利布的依从率为 95.8%±7.6%。一名参与者因漏服剂量被转介给肿瘤医生，一名参与者被转介给财务导航。基线时，33.3%的患者报告至少有一种依从性障碍，包括取药不便、健忘、费用和副作用。在 3 个月内，自我报告的依从性、症状负担或生活质量没有变化。连接的定制化治疗平台的可用性评分为 61.9±14.2。
连接的定制化治疗平台干预措施是可行的，可实现高帕博西利布依从率，且不会随着时间的推移而下降。未来的工作应重点提高可用性。
